Patricio Massera, AGC Biologics CEO

Of­ten-passed plant in Col­orado has a new own­er, who's al­ready op­er­at­ing near­by

A man­u­fac­tur­ing fa­cil­i­ty in Long­mont, CO will have new oc­cu­pants soon.

AGC Bi­o­log­ics, a CD­MO with head­quar­ters in Den­mark, signed a pur­chase agree­ment to take over a cell and gene ther­a­py site that’s cur­rent­ly owned by No­var­tis.

No­var­tis leased the site from As­traZeneca just a lit­tle over a year ago, with the hopes of ramp­ing up man­u­fac­tur­ing for Zol­gens­ma, the con­tro­ver­sial gene ther­a­py for chil­dren younger than 2 years old with at­ro­phy. At the end of March, a No­var­tis spokesper­son said that the com­pa­ny would leave Long­mont by Ju­ly “at the lat­est,” which would leave 400 em­ploy­ees with­out a job. It was the sec­ond Col­orado plant the com­pa­ny had walked away from in the last four years, as it shut­tered Broom­field op­er­a­tions and cut 450 jobs over two years due to de­clin­ing sales.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.